非小细胞肺癌肝转移免疫微环境研究进展及治疗策略OA北大核心CSTPCD
Treatment Strategy and Research Progress of Immune Microenvironment for Liver Metastasis of Non-small Cell Lung Cancer
肝脏是非小细胞肺癌转移扩散的常见部位,且肺癌肝转移患者的预后不良,或许与肝脏特异性微环境组成有关.多种病理生理因素的调控,包括肝脏免疫微环境、相关细胞、蛋白、信号分子及基因改变,都会对肺癌肝转移过程及后续的治疗策略产生影响.近年来,免疫检查点抑制剂治疗在晚期非小细胞肺癌患者中取得了突破性进展,但作为晚期肺癌的特殊人群,非小细胞肺癌肝转移患者具有免疫治疗较差的特点.本文对免疫微环境影响肝转移发生发展的相关机制加以综述,总结抗肿瘤免疫疗法在非小细胞肺癌肝转移中取得的成果及前景展望.
Liver is the common site for metastasis and spread of non-small cell lung cancer(NSCLC).Lung cancer patients with liver metastasis have poor prognosis,which may be related to liver-specific microenvironment composition.The metastasis of lung cancer to the liver is regulated by various pathophysiological factors,including the liver immune microenvironment,related cells,proteins,signaling molecules,and gene changes.These factors will affect the consistent disease process and subsequent treatment strategies.Immune checkpoint inhibitors(ICIs)have made breakthroughs in treatment of patients with advanced NSCLC.However,NSCLC patients with liver metastasis,a unique population of advanced lung cancer,are characterized by poor immunotherapeutic effect.This paper reviews the related mechanisms of the immune microenvironment in affecting the occurrence and development of liver metastases and summarizes the achievements and prospects of anti-tumor immunotherapy in liver metastases of NSCLC.
孙家齐;王玉栋
050011 石家庄,河北医科大学第四医院肿瘤内科
临床医学
非小细胞肺癌肝转移免疫治疗免疫微环境
Non-small cell lung cancerLiver metastasisImmunotherapyImmune microenvironment
《肿瘤防治研究》 2024 (003)
203-209 / 7
S&T Program of Hebei(No.236Z7729G);Natural Science Foundation of Hebei Province(No.H2020206551);Beijing Xisike Clinical Oncology Research Foundation(No.Y-MSDPU2021-0202) 河北省科技厅项目(236Z7729G);河北省自然科学基金(H2020206551);北京市希思科临床肿瘤学研究基金(Y-MSDPU2021-0202)
评论